Development and validation of a novel cell-based assay for potency determination of human parathyroid hormone (PTH)

Journal of Pharmaceutical and Biomedical Analysis

Volumn 98, Issue , 2014, Pages 345-350

  Hohenstein, Axel ^a   Hebell, Meike ^a   Zikry, Heidi ^b   El Ghazaly, Maria ^b   Mueller, Frank ^b   Rohde, Jan ^b  

^a Bioassay Labor fuer biologische Analytik GmbH   (Germany)

^b Minapharm Pharmaceuticals   (Egypt)

Author keywords

HEK293; Immunogenicity testing; Parathyroid hormone; Potency assay; TR FRET

Indexed keywords

CYCLIC AMP; NEUTRALIZING ANTIBODY; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RECOMBINANT PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR 1; PTH PROTEIN, HUMAN; PTH1R PROTEIN, HUMAN;

ACCURACY; ARTICLE; CONTROLLED STUDY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HEK293 CELL LINE; HUMAN; HUMAN TISSUE; IMMUNOGENICITY; LIMIT OF QUANTITATION; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; BIOASSAY; BLOOD; CELL LINE; FLUORESCENCE; METABOLISM; PROCEDURES; SENSITIVITY AND SPECIFICITY;

ANTIBODIES, NEUTRALIZING; BIOLOGICAL ASSAY; CELL LINE; CYCLIC AMP; FLUORESCENCE; HEK293 CELLS; HUMANS; PARATHYROID HORMONE; RECEPTOR, PARATHYROID HORMONE, TYPE 1; SENSITIVITY AND SPECIFICITY;

EID: 84903746449     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2014.06.004     Document Type: Article

References (29)

1. Osteoporosis Prevention, Diagnosis, and Therapy. NIH Concensus Statement 2000 March 27-29; 17(1): 1-45.
2. International Osteoporosis Foundation Facts and Statistics 2013, International Osteoporosis Foundation, Available at http://www.osteofound.org/facts-statistics#category-14 (accessed February 18, 2013).
3. Cooper C. Epidemiology of osteoporosis. Osteoporosis Int. 1999, 9(Suppl. 2):S2-S8.
4. Cummings S.R., Melton L.J. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002, 359:1761-1767.
5. Genant H.K., Cooper C., Poor G., Reid I., Ehrlich G., Kanis J. Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporosis Int. 1999, 10:259-264.
6. Rosen C.J., Chesnut C.H., Mallinak N.J. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J. Clin. Endocrinol. Metab. 1997, 82:1904-1910.
7. Greenspan S.L., Parker R.A., Ferguson L., Rosen H.N., Maitland-Ramsey L., Karpf D.B. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J. Bone Miner. Res. 1998, 13:1431-1438.
8. T. Luhmann, O., Germershaus, J., Groll, L. Meinel, Bone targeting for the treatment of osteoporosis, J. Controlled Release, doi: 10.1016/j.jconrel.2011.10.001.
9. Verhaar H.J.J., Lems W.F. PTH-analogs: comparable or different?. Arch. Gerontol. Geriatr. 2009, 49:e130-e132.
10. Sikon A., Batur P. Profile of teriparatide in the management of postmenopausal osteoporosis. Int. J. Womens Health 2010, 2:37-44.
11. EMA. -Scientific discussion for Forsteo taken from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000425/WC500027992.pdf.
12. EMA. Scientific discussion Preotact taken from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000659/WC500041340.pdf.
13. Offermanns S., Iida-Klein A., Segre G.V., Simon M.I. G alpha q family members couple parathyroid hormone (PTH)/PTH-related peptide and calcitonin receptors to phospholipase C in COS-7 cells. Mol. Endocrinol. 1996, 10:566-574.
14. Schwindinger W.F., Fredericks J., Watkins L., Robinson H., Bathon J.M., Pines M., Suva L.J., Levine M.A. Coupling of the PTH/PTHrP receptor to multiple G-proteins. Direct demonstration of receptor activation of Gs, Gq/11, and Gi(1) by [alpha-32P]GTP-gamma-azidoanilide photo affinity labeling. Endocrine 1998, 8:201-209.
15. 3 secretion. J. Clin. Invest. 1992, 90:2278-2283.
16. Jobert A.S., Leroy C., Butlen D., Silvre C. Parathyroid hormone-induced calcium release from intracellular stores in a human kidney cell line in the absence of stimulation of cyclic adenosine 3'5'-monophosphate production. Endocrinology 1997, 138:5282-5292.
17. +/Pi cotransporter in mouse kidney. Pflugers Arch.-Eur. J. Physiol. 2003, 446:52-60.
18. Cohen J.A. Parathyroid hormone activates mitogen-activated protein kinase in opossum kidney cells. Endocrinology 1999, 140:5771-5779.
19. Singh A.T., Bhattacharyya R.S., Radeff J.M., Stern P.H. Regulation of parathyroid hormone-stimulated phospholipase D in UMR-106 cells by calcium, MAP kinase, and small G proteins. J. Bone Miner Res. 2003, 18:1453-1460.
20. Garrido J.L., Wheeler D., Vega L.C., Friedman P.A., Romero G. Role of phospholipase D in parathyroid hormone type 1 receptor signaling and trafficking. Mol. Endocrinol. 2009, 12:2048-2059.
21. Murrils R.J., Matteo J.J., Samuel R.L., Andrews J.L., Bhat B.M., Coleburn V.E., Kharode Y.P., Bex F.J. In vitro and in vivo activities of C-terminally truncated PTH peptides reveal a disconnection between cAMP signaling and functional activity. Bone 2004, 35:1263-1272.
22. Dietrich J.W., Canalis E.M., Maina D.M., Raisz L.G. Hormonal control of bone collagen synthesis in vitro: effects of parathyroid hormone and calcitonin. Endocrinology 1976, 98:943-949.
23. Boland C.J., Fried R.M., Tashjian A.H. Measurement of cytosolic free Ca concentrations in human and rat osteosarcoma cells: actions, of bone resorption stimulating hormones. Endocrinology 1986, 118:980-989.
24. 2+ in the osteosarcoma cell line UMR-106-01. Biosci. Rep. 1992, 12:207-214.
25. Rafferty B., Gains-Das R.E. WHO international collaboration study of the proposed 1st international standard for parathyroid hormone 1-34, recombinant, human. WHO/BS/07.2063 2007.
26. ICH Harmonized tripartite guideline Q2 (R1): validation of analytical procedures: text and methodology. International Conference on Harmonization (ICH) 2005.
27. Inomata N., Akiyama M., Kubota N., Jueppner H. Characterization of a novel parathyroid hormone (PTH) receptor with specificity for the carboxyl-terminal region of PTH (1-84). Endocrinology 1995, 136:4732-4740.
28. Divieti P., Gello A.I., Sulimann G., Jueppner H., Bringhurst F.R. Receptors specific for the carboxy-terminal region of parathyroid hormone on bone-derived cells: determinants of ligand binding and bioactivity. Endocrinology 2005, 146:1863-1870.
29. Hodsman A.B., Bauer D.C., Dempster D.W., Dian L., Hanley D.A., Harris S.T., Kendler D.L., McClung M.R., Miller P.D., Olszybski W.P., Orwoll E., Yuen C.K. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr. Rev. 2005, 26:688-703.